{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:01:41Z","timestamp":1793289701242,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403999"],"award-info":[{"award-number":["82403999"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573611"],"award-info":[{"award-number":["82573611"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02649-w","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:57:52Z","timestamp":1775548672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Activation of Nerve Growth Factor signaling limits the response to lenvatinib in hepatocellular carcinoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Minghao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longtao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongchi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bugang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwu","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-629X","authenticated-orcid":false,"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,5]]},"reference":[{"key":"2649_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang, J. D. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 16, 589\u2013604, https:\/\/doi.org\/10.1038\/s41575-019-0186-y (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2649_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel, A., Meyer, T., Sapisochin, G., Salem, R. & Saborowski, A. Hepatocellular carcinoma. Lancet (Lond., Engl.) 400, 1345\u20131362, https:\/\/doi.org\/10.1016\/S0140-6736(22)01200-4 (2022).","journal-title":"Lancet (Lond., Engl.)"},{"key":"2649_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390, https:\/\/doi.org\/10.1056\/NEJMoa0708857 (2008).","journal-title":"N. Engl. J. Med."},{"key":"2649_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163\u20131173, https:\/\/doi.org\/10.1016\/s0140-6736(18)30207-1 (2018).","journal-title":"Lancet"},{"key":"2649_CR5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin, H. et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature 595, 730\u2013734, https:\/\/doi.org\/10.1038\/s41586-021-03741-7 (2021).","journal-title":"Nature"},{"key":"2649_CR6","doi-asserted-by":"publisher","unstructured":"Liang, B. G. et al. The MASTL\/YBX1\/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC. Hepatology (Baltimore, Md.) https:\/\/doi.org\/10.1097\/hep.0000000000001392 (2025).","DOI":"10.1097\/hep.0000000000001392"},{"key":"2649_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102208","volume":"6","author":"M Xu","year":"2025","unstructured":"Xu, M. et al. CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma. Cell Rep. Med. 6, 102208. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102208 (2025).","journal-title":"Cell Rep. Med."},{"key":"2649_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jbior.2014.11.003","volume":"58","author":"RA Bradshaw","year":"2015","unstructured":"Bradshaw, R. A. et al. NGF and ProNGF: regulation of neuronal and neoplastic responses through receptor signaling. Adv. Biol. Regul. 58, 16\u201327, https:\/\/doi.org\/10.1016\/j.jbior.2014.11.003 (2015).","journal-title":"Adv. Biol. Regul."},{"key":"2649_CR9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1126\/science.3306916","volume":"237","author":"R Levi-Montalcini","year":"1987","unstructured":"Levi-Montalcini, R. The nerve growth factor 35 years later. Science (N. Y., N. Y.) 237, 1154\u20131162 (1987).","journal-title":"Science (N. Y., N. Y.)"},{"key":"2649_CR10","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2174\/1570159x16666180412092859","volume":"16","author":"ML Rocco","year":"2018","unstructured":"Rocco, M. L., Soligo, M., Manni, L. & Aloe, L. Nerve growth factor: early studies and recent clinical trials. Curr. Neuropharmacol. 16, 1455\u20131465, https:\/\/doi.org\/10.2174\/1570159x16666180412092859 (2018).","journal-title":"Curr. Neuropharmacol."},{"key":"2649_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ccell.2017.11.007","volume":"33","author":"BW Renz","year":"2018","unstructured":"Renz, B. W. et al. \u03b22 adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell 33, 75\u201390.e77, https:\/\/doi.org\/10.1016\/j.ccell.2017.11.007 (2018).","journal-title":"Cancer Cell"},{"key":"2649_CR12","doi-asserted-by":"publisher","first-page":"7014","DOI":"10.1158\/0008-5472.Can-14-1220","volume":"74","author":"G McCaffrey","year":"2014","unstructured":"McCaffrey, G. et al. NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use. Cancer Res. 74, 7014\u20137023, https:\/\/doi.org\/10.1158\/0008-5472.Can-14-1220 (2014).","journal-title":"Cancer Res."},{"key":"2649_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s42003-020-01549-1","volume":"4","author":"WY Chen","year":"2021","unstructured":"Chen, W. Y. et al. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. Commun. Biol. 4, 22, https:\/\/doi.org\/10.1038\/s42003-020-01549-1 (2021).","journal-title":"Commun. Biol."},{"key":"2649_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6736","volume":"13","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Heterogeneity-induced NGF-NGFR communication inefficiency promotes mitotic spindle disorganization in exhausted T cells through PREX1 suppression to impair the anti-tumor immunotherapy with PD-1 mAb in hepatocellular carcinoma. Cancer Med. 13, e6736. https:\/\/doi.org\/10.1002\/cam4.6736 (2024).","journal-title":"Cancer Med."},{"key":"2649_CR15","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1053\/gast.2002.33581","volume":"122","author":"K Kishibe","year":"2002","unstructured":"Kishibe, K., Yamada, Y. & Ogawa, K. Production of nerve growth factor by mouse hepatocellular carcinoma cells and expression of TrkA in tumor-associated arteries in mice. Gastroenterology 122, 1978\u20131986, https:\/\/doi.org\/10.1053\/gast.2002.33581 (2002).","journal-title":"Gastroenterology"},{"key":"2649_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13046-019-1104-4","volume":"38","author":"T Luo","year":"2019","unstructured":"Luo, T. et al. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth. J. Exp. Clin. Cancer Res. CR 38, 130, https:\/\/doi.org\/10.1186\/s13046-019-1104-4 (2019).","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"2649_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbrc.2011.01.116","volume":"406","author":"W Jin","year":"2011","unstructured":"Jin, W. et al. DNA methylation-dependent regulation of TrkA, TrkB, and TrkC genes in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 406, 89\u201395, https:\/\/doi.org\/10.1016\/j.bbrc.2011.01.116 (2011).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2649_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41580-022-00545-z","volume":"24","author":"LE Marasco","year":"2023","unstructured":"Marasco, L. E. & Kornblihtt, A. R. The physiology of alternative splicing. Nat. Rev. Mol. Cell Biol. 24, 242\u2013254, https:\/\/doi.org\/10.1038\/s41580-022-00545-z (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2649_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.molcel.2019.09.017","volume":"76","author":"J Ule","year":"2019","unstructured":"Ule, J. & Blencowe, B. J. Alternative splicing regulatory networks: functions, mechanisms, and evolution. Mol. Cell 76, 329\u2013345, https:\/\/doi.org\/10.1016\/j.molcel.2019.09.017 (2019).","journal-title":"Mol. Cell"},{"key":"2649_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","volume":"23","author":"RK Bradley","year":"2023","unstructured":"Bradley, R. K. & Anczuk\u00f3w, O. RNA splicing dysregulation and the hallmarks of cancer. Nat. Rev. Cancer 23, 135\u2013155, https:\/\/doi.org\/10.1038\/s41568-022-00541-7 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"2649_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","volume":"17","author":"SC Bonnal","year":"2020","unstructured":"Bonnal, S. C., L\u00f3pez-Oreja, I. & Valc\u00e1rcel, J. Roles and mechanisms of alternative splicing in cancer\u2014implications for care. Nat. Rev. Clin. Oncol. 17, 457\u2013474, https:\/\/doi.org\/10.1038\/s41571-020-0350-x (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2649_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100728","volume":"53","author":"R Sciarrillo","year":"2020","unstructured":"Sciarrillo, R. et al. The role of alternative splicing in cancer: From oncogenesis to drug resistance. Drug Resist Updat 53, 100728. https:\/\/doi.org\/10.1016\/j.drup.2020.100728 (2020).","journal-title":"Drug Resist Updat"},{"key":"2649_CR23","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/s41592-024-02235-4","volume":"21","author":"W Hou","year":"2024","unstructured":"Hou, W. & Ji, Z. Assessing GPT-4 for cell type annotation in single-cell RNA-seq analysis. Nat. Methods 21, 1462\u20131465, https:\/\/doi.org\/10.1038\/s41592-024-02235-4 (2024).","journal-title":"Nat. Methods"},{"key":"2649_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41586-019-1373-2","volume":"572","author":"N Aizarani","year":"2019","unstructured":"Aizarani, N. et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature 572, 199\u2013204, https:\/\/doi.org\/10.1038\/s41586-019-1373-2 (2019).","journal-title":"Nature"},{"key":"2649_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrn1078","volume":"4","author":"MV Chao","year":"2003","unstructured":"Chao, M. V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci. 4, 299\u2013309 (2003).","journal-title":"Nat. Rev. Neurosci."},{"key":"2649_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41568-019-0237-2","volume":"20","author":"AH Zahalka","year":"2020","unstructured":"Zahalka, A. H. & Frenette, P. S. Nerves in cancer. Nat. Rev. Cancer 20, 143\u2013157, https:\/\/doi.org\/10.1038\/s41568-019-0237-2 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2649_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.molcel.2021.10.010","volume":"82","author":"W Xu","year":"2022","unstructured":"Xu, W., Biswas, J., Singer, R. H. & Rosbash, M. Targeted RNA editing: novel tools to study post-transcriptional regulation. Mol. Cell 82, 389\u2013403, https:\/\/doi.org\/10.1016\/j.molcel.2021.10.010 (2022).","journal-title":"Mol. Cell"},{"key":"2649_CR28","doi-asserted-by":"publisher","unstructured":"Choquet, K., Patop, I. L. & Churchman, L. S. The regulation and function of post-transcriptional RNA splicing. Nat. Rev. Genet. https:\/\/doi.org\/10.1038\/s41576-025-00836-z (2025).","DOI":"10.1038\/s41576-025-00836-z"},{"key":"2649_CR29","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/319784a0","volume":"319","author":"RH Edwards","year":"1986","unstructured":"Edwards, R. H., Selby, M. J. & Rutter, W. J. Differential RNA splicing predicts two distinct nerve growth factor precursors. Nature 319, 784\u2013787 (1986).","journal-title":"Nature"},{"key":"2649_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104812","volume":"140","author":"M Soligo","year":"2020","unstructured":"Soligo, M. et al. Construction and preliminary characterization of human recombinant proNGF-A variant. Neurochem. Int. 140, 104812. https:\/\/doi.org\/10.1016\/j.neuint.2020.104812 (2020).","journal-title":"Neurochem. Int."},{"key":"2649_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/bjc.2014.342","volume":"111","author":"MV Gammons","year":"2014","unstructured":"Gammons, M. V. et al. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br. J. Cancer 111, 477\u2013485, https:\/\/doi.org\/10.1038\/bjc.2014.342 (2014).","journal-title":"Br. J. Cancer"},{"key":"2649_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.molcel.2015.09.005","volume":"60","author":"O Anczuk\u00f3w","year":"2015","unstructured":"Anczuk\u00f3w, O. et al. SRSF1-regulated alternative splicing in breast cancer. Mol. Cell 60, 105\u2013117, https:\/\/doi.org\/10.1016\/j.molcel.2015.09.005 (2015).","journal-title":"Mol. Cell"},{"key":"2649_CR33","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/0008-5472.Can-06-2969","volume":"67","author":"GM Hayes","year":"2007","unstructured":"Hayes, G. M., Carrigan, P. E. & Miller, L. J. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res. 67, 2072\u20132080, https:\/\/doi.org\/10.1158\/0008-5472.Can-06-2969 (2007).","journal-title":"Cancer Res."},{"key":"2649_CR34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2008.02.009","volume":"29","author":"DY Mao","year":"2008","unstructured":"Mao, D. Y., Ceccarelli, D. F. & Sicheri, F. Unraveling the tail\u201d of how SRPK1 phosphorylates ASF\/SF2. Mol. Cell 29, 535\u2013537, https:\/\/doi.org\/10.1016\/j.molcel.2008.02.009 (2008).","journal-title":"Mol. Cell"},{"key":"2649_CR35","doi-asserted-by":"publisher","unstructured":"Nikas, I. P., Themistocleous, S. C., Paschou, S. A., Tsamis, K. I. & Ryu, H. S. Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives. Cells 9 https:\/\/doi.org\/10.3390\/cells9010019 (2019).","DOI":"10.3390\/cells9010019"},{"key":"2649_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/path.4846","volume":"241","author":"N Bullock","year":"2017","unstructured":"Bullock, N. & Oltean, S. The many faces of SRPK1. J. Pathol. 241, 437\u2013440, https:\/\/doi.org\/10.1002\/path.4846 (2017).","journal-title":"J. Pathol."},{"key":"2649_CR37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298\u2013307, https:\/\/doi.org\/10.1038\/nature10144 (2011).","journal-title":"Nature"},{"key":"2649_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejphar.2015.05.030","volume":"762","author":"L Zhang","year":"2015","unstructured":"Zhang, L., Tu, Y., He, W., Peng, Y. & Qiu, Z. A novel mechanism of hepatocellular carcinoma cell apoptosis induced by lupeol via Brain-Derived Neurotrophic Factor Inhibition and Glycogen Synthase Kinase 3 beta reactivation. Eur. J. Pharm. 762, 55\u201362, https:\/\/doi.org\/10.1016\/j.ejphar.2015.05.030 (2015).","journal-title":"Eur. J. Pharm."},{"key":"2649_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25967-9","volume":"12","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Environmental eustress modulates \u03b2-ARs\/CCL2 axis to induce anti-tumor immunity and sensitize immunotherapy against liver cancer in mice. Nat. Commun. 12, 5725. https:\/\/doi.org\/10.1038\/s41467-021-25967-9 (2021).","journal-title":"Nat. Commun."},{"key":"2649_CR40","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1158\/0008-5472.CAN-20-2793","volume":"81","author":"DA Silverman","year":"2021","unstructured":"Silverman, D. A. et al. Cancer-associated neurogenesis and nerve-cancer cross-talk. Cancer Res. 81, 1431\u20131440, https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-2793 (2021).","journal-title":"Cancer Res."},{"key":"2649_CR41","doi-asserted-by":"publisher","unstructured":"Lin, H. et al. Nerve growth factor regulates liver cancer cell polarity and motility. Mol. Med. Rep. 23 https:\/\/doi.org\/10.3892\/mmr.2021.11927 (2021).","DOI":"10.3892\/mmr.2021.11927"},{"key":"2649_CR42","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.7150\/ijbs.72982","volume":"18","author":"Z Yang","year":"2022","unstructured":"Yang, Z. et al. Neurotrophin3 promotes hepatocellular carcinoma apoptosis through the JNK and P38 MAPK pathways. Int. J. Biol. Sci. 18, 5963\u20135977, https:\/\/doi.org\/10.7150\/ijbs.72982 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"2649_CR43","doi-asserted-by":"publisher","first-page":"e426","DOI":"10.1038\/emm.2017.235","volume":"50","author":"MS Tsai","year":"2018","unstructured":"Tsai, M. S. et al. Nerve growth factor upregulates sirtuin 1 expression in cholestasis: a potential therapeutic target. Exp. Mol. Med. 50, e426, https:\/\/doi.org\/10.1038\/emm.2017.235 (2018).","journal-title":"Exp. Mol. Med."},{"key":"2649_CR44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13046-024-03202-9","volume":"43","author":"Y Zheng","year":"2024","unstructured":"Zheng, Y. et al. Mechanisms of neural infiltration-mediated tumor metabolic reprogramming impacting immunotherapy efficacy in non-small cell lung cancer. J. Exp. Clin. Cancer Res. 43, 284, https:\/\/doi.org\/10.1186\/s13046-024-03202-9 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2649_CR45","doi-asserted-by":"publisher","unstructured":"Yang, P. et al. CAR T cells secreting NGF-neutralizing scFv enhance efficacy in clear cell renal cell carcinoma by relieving immunosuppression through immunosympathectomy. J Immunother. Cancer 12 https:\/\/doi.org\/10.1136\/jitc-2024-009910 (2024).","DOI":"10.1136\/jitc-2024-009910"},{"key":"2649_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar, M. E., Kim, H. J. & Kim, D. R. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct. Target Ther. 8, 455, https:\/\/doi.org\/10.1038\/s41392-023-01705-z (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2649_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bbcan.2011.10.002","volume":"1825","author":"BA Drew","year":"2012","unstructured":"Drew, B. A., Burow, M. E. & Beckman, B. S. MEK5\/ERK5 pathway: The first fifteen years. Biochim. Biophys. Acta (BBA) Rev. Cancer 1825, 37\u201348, https:\/\/doi.org\/10.1016\/j.bbcan.2011.10.002 (2012).","journal-title":"Biochim. Biophys. Acta (BBA) Rev. Cancer"},{"key":"2649_CR48","doi-asserted-by":"publisher","first-page":"viii16","DOI":"10.1093\/annonc\/mdz384","volume":"30","author":"JP Solomon","year":"2019","unstructured":"Solomon, J. P., Benayed, R., Hechtman, J. F. & Ladanyi, M. Identifying patients with NTRK fusion cancer. Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol. 30, viii16\u2013viii22, https:\/\/doi.org\/10.1093\/annonc\/mdz384 (2019).","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"key":"2649_CR49","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 21, 531\u2013540, https:\/\/doi.org\/10.1016\/S1470-2045(19)30856-3 (2020).","journal-title":"Lancet Oncol."},{"key":"2649_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00427-3","volume":"7","author":"Y Xu","year":"2023","unstructured":"Xu, Y. et al. Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China. NPJ Precis. Oncol. 7, 75. https:\/\/doi.org\/10.1038\/s41698-023-00427-3 (2023).","journal-title":"NPJ Precis. Oncol."},{"key":"2649_CR51","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.Cd-12-0108","volume":"2","author":"K Takezawa","year":"2012","unstructured":"Takezawa, K. et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2, 922\u2013933, https:\/\/doi.org\/10.1158\/2159-8290.Cd-12-0108 (2012).","journal-title":"Cancer Discov."},{"key":"2649_CR52","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med 378, 731\u2013739, https:\/\/doi.org\/10.1056\/NEJMoa1714448 (2018).","journal-title":"N. Engl. J. Med"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02649-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02649-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02649-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:57:53Z","timestamp":1775548673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02649-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2649"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02649-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,5]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}